Real‐World Experience Using Sodium Thiosulfate Pentahydrate Off‐Label for Cisplatin Otoprotection in Children, Adolescents, and Young Adults
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31631 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Julie Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Cisplatin, Thiosulfates, Off-Label Use, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Unravel Pediatric Cancer Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Cisplatin is used to treat solid tumors but causes irreversible hearing loss. Pedmark, a formulation of sodium thiosulfate (STS), is approved to prevent cisplatin‐induced hearing loss (CIHL). Prior to approval, non‐Pedmark formulations of STS pentahydrate (STS‐P) were prescribed off‐label for otoprotection and continue to be used in the absence of data. Procedure This multicenter retrospective study examined tolerability, toxicity, and hearing outcomes of STS‐P used off‐label for otoprotection. Exploratory analyses compared toxicity and hearing data in patients receiving STS‐P versus the pre‐Pedmark investigational formulation (STS‐inv) tested in trials.
Results
Fifty‐nine patients received STS‐P (16 or 20 g/m 2 ). Infusion‐related reactions (IRR) occurred in 14% (8/59), more commonly in patients receiving 20 g/m 2 . No severe adverse events occurred. One patient (2%) discontinued STS‐P for IRR. The prevalence of CIHL (International Society of Paediatric Oncology [SIOP] Grade ≥2) at the end of therapy and at the most recent hearing assessment was 30% at both timepoints (12/40 and 8/27, respectively). In exploratory analyses comparing STS‐P with STS‐inv ( n = 14), there was no difference in tolerance or toxicity. In multivariable analysis, a lower risk for CIHL at the end of therapy was found for age ≥5 years, higher dosing of 20 g/m 2 , and received STS‐inv (odds ratio 0.02, 95% confidence interval: 0.0003–0.691, p < 0.01). No difference was present at the most recent exam.
Conclusions
STS‐P off‐label for otoprotection following cisplatin was tolerable in a real‐world setting across age groups and cancer types. Formal testing in larger studies of different STS formulations is needed to explore possible differences in toxicity and CIHL prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
- Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
- BC Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
- Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Department of Pharmacy, Children's Hospital Los Angeles, Los Angeles, California, USA.
ORCID-Profile: Julie Ma, Hannah E Sauer, David R Freyer, Etan Orgel
Förderung
- Unravel Pediatric Cancer Foundation
Zitieren
APA
Ma, J., Foster, J. H., Rassekh, S. R., Malvar, J., Chi, Y. Y., Sauer, H. E., Jeon, J., Freyer, D. R., Rushing, T., & Orgel, E. (2025). Real‐World Experience Using Sodium Thiosulfate Pentahydrate Off‐Label for Cisplatin Otoprotection in Children, Adolescents, and Young Adults. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31631
Vancouver
Ma J, Foster JH, Rassekh SR, Malvar J, Chi YY, Sauer HE, et al. Real‐World Experience Using Sodium Thiosulfate Pentahydrate Off‐Label for Cisplatin Otoprotection in Children, Adolescents, and Young Adults. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31631
BibTeX
@article{Ma2025,
author = {Ma, Julie and Foster, Jennifer H and Rassekh, Shahrad R and Malvar, Jemily and Chi, Yueh-Yun and Sauer, Hannah E and Jeon, Jessica and Freyer, David R and Rushing, Teresa and Orgel, Etan},
title = {Real‐World Experience Using Sodium Thiosulfate Pentahydrate Off‐Label for Cisplatin Otoprotection in Children, Adolescents, and Young Adults},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31631}
}
EUVIMED